Similar articles

• The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.

  Eschbach JW, Haley NR, Adamson JW. Eschbach JW, et al. Contrib Nephrol. 1990;78:24-36; discussion 37. Contrib Nephrol. 1990. PMID: 2225841 Review. No abstract available.
• [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].

  von Appen K, Klinkmann H. von Appen K, et al. Urol Nefrol (Mosk). 1990 Nov-Dec;(6):69-70. Urol Nefrol (Mosk). 1990. PMID: 2089771 Review. Russian. No abstract available.
• Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.

  Nissenson AR. Nissenson AR. Semin Nephrol. 1989 Mar;9(1 Suppl 2):25-31. Semin Nephrol. 1989. PMID: 2669083 Review.
• Advances in the management of chronic renal failure: the use of epoetin alfa in clinical practice. Proceedings of a symposium. June 6, 1989, Nashville, TN.

  [No authors listed] [No authors listed] Pharmacotherapy. 1990 Mar-Apr;10(2 ( Pt 2)):1S-26S. Pharmacotherapy. 1990. PMID: 2345707 No abstract available.
• Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.

  Ramírez B, Flores A, Pérez F, Córdoba C, García L, Vázquez G. Ramírez B, et al. Transplant Proc. 1991 Apr;23(2):1833-4. Transplant Proc. 1991. PMID: 2053170 No abstract available.